Abstract
Neurodegeneration in MS and NMO: The Eye and the Blood
Highlights
It seems timely to express our gratitude to the referees who carefully revised the 19 papers submitted to this first special issue of a new journal
What perhaps few of us in the field of multiple sclerosis realized is that patients rank loss of visual function second only to loss of mobility [1]
From Spain, conclude that optical coherence tomography (OCT) may “represent an objective outcome measure” for treatment trials in “Optical coherence tomography in multiple sclerosis and neuromyelitis optica: an update” several therapeutic trials in MS utilizing OCT as a secondary outcome measure are in advanced planning stages
Summary
It seems timely to express our gratitude to the referees who carefully revised the 19 papers submitted to this first special issue of a new journal. What perhaps few of us in the field of multiple sclerosis realized is that patients rank loss of visual function second only to loss of mobility [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
